Start with the question the MDT must actually settle
Brain metastases are not a single disease. The same imaging finding can call for very different decisions depending on the primary cancer, how well it is controlled outside the brain, what brain-directed treatment has already been given, and the patient's neurological condition. A multidisciplinary discussion is useful because no single specialty owns all of those variables. The point is not to collect opinions for their own sake, but to produce one coherent plan that a patient and family can understand.
For an overseas patient, the practical question is narrower than 'does this hospital have an MDT?' It is: what decisions need to be made, which specialties must contribute, and what will happen if the hospital does not run a formal multidisciplinary meeting? A hospital may still coordinate several specialists through sequential consultations, joint clinics, or a case conference that is not labelled as an MDT. The label matters less than whether the relevant questions are answered and recorded.
This guide is for patients who already have a diagnosis of brain metastases, or whose records suggest it and need clarification. It does not recommend a specific treatment. Radiotherapy, for example, uses radiation to treat cancer, and the technique and schedule depend on the individual treatment plan. Whether radiotherapy, surgery, systemic therapy, or a combination is appropriate is a clinical decision that the treating team must make after reviewing the full case.
The primary cancer record is not background — it is a decision input
A common gap in overseas enquiries is a brain imaging report without a clear summary of the primary cancer. That is a problem because the biology of the primary tumour, its current status, and any prior systemic treatment strongly influence what can be offered for brain disease. A pathology report, staging summary, and a short timeline of systemic treatments are therefore not optional extras. They are part of the question.
Ask the treating team to confirm which primary cancer is being treated, when it was diagnosed, what systemic therapies have been used, and whether the extracranial disease is stable, responding, or progressing. If the primary is unknown or the pathology is unclear, ask whether pathology review is needed before a plan can be settled. This is not a bureaucratic step; it changes which options are realistic.
For the MDT discussion itself, the useful output is a statement such as: 'The primary cancer is X, currently controlled/uncontrolled in the following sites, and prior treatments were Y.' Without that, a discussion about the brain can drift into generalities. If the hospital cannot provide that summary, ask who will assemble it and what records they need from you.
Previous brain treatment changes what can be offered now
Prior brain-directed treatment is one of the most important pieces of history. Whole-brain radiotherapy, stereotactic radiosurgery, surgery, or previous systemic therapy that crosses into the brain can all affect what is safe and reasonable next. The MDT needs to know not only what was done, but when, to which areas, and with what clinical and imaging response.
Ask for a clear statement of prior brain treatment, including dates, target areas, and any recorded toxicity. If the patient has had more than one course of brain radiotherapy, the cumulative dose to critical structures becomes a specific question for the radiation oncologist. Do not assume that a new course is automatically possible; ask what the treating team needs to review before deciding.
This is also where the distinction between consultation, planning, and delivery matters. A specialist consultation may confirm that radiotherapy is being considered, but the actual technique and schedule are set during planning, after imaging and dosimetry review. For an overseas patient, ask which stage you are in and what still needs to be confirmed before a treatment date can be discussed.
Local brain control and systemic disease control must be discussed together
Brain metastases are often treated with a combination of local and systemic approaches. Local options may include surgery, radiotherapy, or other focal techniques. Systemic options depend on the primary cancer and may include targeted therapy, immunotherapy, chemotherapy, or other agents. The MDT's job is to decide how these interact, not to list them independently.
Ask the team to explain, in plain language, what the goal of each proposed treatment is: control of the brain lesion, control of symptoms, control of systemic disease, or a combination. Ask what would happen if one part of the plan is delayed or not possible. Ask whether the proposed sequence is fixed or whether it can be adjusted based on response.
For patients considering care in China, this is also the point to ask how the hospital coordinates between specialties. If there is no formal MDT, ask which named specialist is responsible for integrating the plan, how the other specialists' recommendations are communicated, and how the final decision is documented. A written summary that the patient can keep is more useful than a verbal impression.
Neurological symptoms and steroid or seizure management need explicit answers
Brain metastases can cause headaches, seizures, weakness, or changes in alertness. These symptoms affect both the urgency of treatment and the choice of approach. The MDT should address current neurological status, whether there is raised intracranial pressure or a risk of herniation, and whether any urgent intervention is needed before a definitive plan.
Ask specifically about seizure control, steroid use, and any medication that affects fitness for procedures. Do not change or stop any medication on your own. If the patient is currently stable, ask what warning signs should prompt local emergency care rather than waiting for an overseas appointment. This is a safety question, not a travel question.
If the patient is not stable enough to travel, that should be stated clearly. A records-based review can still be useful, but it does not replace local urgent assessment. The treating team in China cannot manage an acute neurological emergency remotely.
What to ask if the hospital does not offer a formal MDT
Not every hospital runs a formal multidisciplinary meeting, and a formal MDT is not the only way to coordinate care. What matters is whether the relevant specialties review the case and whether their conclusions are integrated. If a hospital does not offer an MDT, ask these questions directly:
Who will review the primary cancer records, the brain imaging, and the prior treatment history? Which specialties will be involved, and will they communicate with each other or only with the patient? Will there be a written plan that states the recommended next step, the alternatives considered, and the main uncertainties? Who is the named clinician responsible for answering follow-up questions?
If the answer is that several specialists will each give an opinion without integration, that is a different service from a coordinated plan. It may still be useful, but the patient should know which one they are getting. For complex cases, a review involving two or three relevant specialties may be arranged, with the scope and fee agreed first. That is a coordination service, not a guarantee of hospital acceptance or a clinical outcome.
A free initial case review can check whether the available diagnosis, records, and main question are clear enough to identify the relevant next step. It is not a diagnosis or a promise of acceptance. If a records-based specialist opinion is needed, a proxy consultation is optional and not a prerequisite for every appointment or operation. The hospital decides suitability after reviewing the case.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.